|
Humanization of a mouse anti-OX40 monoclonal antibody to treat cancer
|
1R43CA159797-01A1
|
$187,201
|
Triglia, Dennis
|
AGONOX, INC.
|
|
Community Clinical Oncology Program
|
5U10CA037422-25
|
$4,499,349
|
BRUNER, DEBORAH
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Bay Area Tumor Institute CCOP
|
2U10CA045461-23
|
$486,165
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-06S1
|
$41,433
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-06S2
|
$75,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-06
|
$2,934,758
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Cancer and Stroma-Targeted Immunotherapy with a Gentically Modified DC Vaccine
|
5R01CA148748-02
|
$329,757
|
Song, Xiao-Tong
|
BAYLOR COLLEGE OF MEDICINE
|
|
Vaccination with IL-15 DC to Generate Melanoma-specific Protective Memory T Cells
|
5R01CA140602-03
|
$395,213
|
PALUCKA, ANNA KAROLINA
|
BAYLOR RESEARCH INSTITUTE
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-28
|
$607,994
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
VEGFs in tumor lymphatic metastasis
|
5R01CA142262-04
|
$452,526
|
DVORAK, HAROLD
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Deconstruction and in vivo functionalization of the ceRNA cancer network (PQ-11)
|
1R01CA170158-01
|
$361,050
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Rectifying defects in tumor vasculature to improve chemo- and radiation therapies
|
5R01CA129339-05
|
$342,168
|
SENGER, DONALD
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Orphan Nuclear Receptor TR3 in tumor angiogenesis and associated microvessel perm
|
5R01CA133235-04
|
$342,168
|
ZENG, HUIYAN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S1
|
$300,000
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S2
|
$139,989
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
5U10CA139519-03
|
$310,336
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
The role of pheomelanin in cutaneous melanoma
|
4R01CA137098-05
|
$339,090
|
Cui, Rutao
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
BMP7 in melanoma niche morphogenesis and homeostasis
|
5R01CA138649-03
|
$329,387
|
HSU, MEI-YU
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Cancer and Leukemia Group B CCOP Research Base
|
3U10CA037447-27S1
|
$405,901
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B CCOP Research Base
|
5U10CA037447-28
|
$2,286,202
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Melanoma Stem Cells, Vasculogenesis and Neoplastic Progression
|
5R01CA138231-05
|
$336,640
|
Frank, Markus
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
SPORE in Skin Cancer
|
5P50CA093683-10
|
$2,300,000
|
KUPPER, THOMAS
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Molecular signatures of melanoma histology and progression: A Population Based A
|
5R01CA137365-04
|
$287,421
|
QURESHI, ABRAR
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Multifunctional nanoparticles for targeting aberrant tumorigenic pathways
|
5R01CA135242-03
|
$359,276
|
Sengupta, Shiladitya
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Integrating Genetics of Gene Expression into Pathway Analysis for Melanoma GWAS
|
1R03CA167741-01
|
$97,615
|
Zhang, Mingfeng
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Stem Cell-Engineered Tumor Immunity in Man
|
5P01CA132681-03
|
$2,898,964
|
BALTIMORE, DAVID
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Strategies for Distinguishing Success in Immunotherapy Treatments (PQ20)
|
1R01CA170689-01
|
$642,768
|
HEATH, JAMES
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Nanosystems Biology Cancer Center 2
|
5U54CA151819-03
|
$2,463,138
|
HEATH, JAMES
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Validation of Genomic Targets in Melanoma
|
5R01CA114337-08
|
$351,145
|
KASHANI-SABET, MOHAMMED
|
CALIFORNIA PACIFIC MED CTR RES INSTITUTE
|
|
Carle Cancer Center Community Clinical Oncology Program
|
5U10CA035195-29
|
$728,213
|
ROWLAND, KENDRITH
|
CARLE FOUNDATION
|
|
Bone Marrow MSCs/Pericytes: Gatekeepers Controlling Skeletal Metastasis.
|
1R01CA163562-01A1
|
$315,367
|
Caplan, Arnold
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-22S3
|
$4,849,180
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-22S4
|
$74,396
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Cedar Rapids Oncology Project
|
5U10CA052352-23
|
$326,434
|
Wilbur, Deborah
|
CEDAR RAPIDS ONCOLOGY PROJECT
|
|
Immunology of human malignant melanoma initiating cells
|
1R01CA158467-01A1
|
$401,127
|
Frank, Markus
|
CHILDREN'S HOSPITAL BOSTON
|
|
Cancer Biology in the Zebrafish
|
5R01CA103846-10
|
$366,757
|
ZON, LEONARD
|
CHILDREN'S HOSPITAL BOSTON
|
|
Delaware/Christiana Care Community Clinical Oncology Program
|
2U10CA045418-26
|
$1,423,934
|
GRUBBS, STEPHEN
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
Research and Mentoring on Energetic Factors and Cancer: Established Investigator
|
5K05CA136967-04
|
$137,885
|
BERNSTEIN, LESLIE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
CCOP: Colorado Cancer Research Program
|
2U10CA067753-17
|
$1,128,806
|
PAJON, EDUARDO
|
COLORADO CANCER RESEARCH PROGRAM, INC.
|
|
Integrative Cancer Genomics: Drivers, Pathways and Drugs
|
1R01CA164729-01A1
|
$399,632
|
Pe'er, Dana
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
Dissecting the Melanoma Genome
|
1R21CA158557-01A1
|
$223,208
|
CELEBI, JULIDE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
GAB2 in metastatic melanoma
|
5R01CA138678-04
|
$324,051
|
CELEBI, JULIDE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-39S1
|
$140,000
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-39S2
|
$75,000
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-39
|
$3,816,425
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Columbia University Medical Center Minority-Based Community Clinical Oncology Pro
|
1U10CA167791-01
|
$796,302
|
GRANN, VICTOR
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Targeting the LKB1-AMPK PATHWAY in Melanoma: Mechanism and Preclinical Evaluation
|
1R01CA166717-01
|
$332,000
|
Zheng, Bin
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Regulation of LKB1 and AMPK Signaling by BRAF in Melanoma
|
5R00CA133245-05
|
$241,530
|
Zheng, Bin
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Columbus Community Clinical Oncology Program (Columbus CCOP)
|
5U10CA035261-29
|
$813,151
|
KUEBLER, J
|
COLUMBUS COMMUNITY CLINICAL ONCOLOGY PRG
|
|
Combination Melanoma Immunotherapy: Antigen Enhancement and Adoptive T Cells
|
1R43CA165553-01
|
$300,000
|
Newton, Estelle
|
CYTOCURE, LLC
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|